Plus Therapeutics' subsidiary CNSide Diagnostics has signed a regional agreement with Medical Mutual to provide the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration assay to about 1.2 million people in Ohio and Kentucky. This expands the total coverage of the CNSide CSF assay to approximately 127 million people nationwide. The assay aids in rapid diagnosis and treatment monitoring for patients with leptomeningeal metastases, showing high accuracy and influencing treatment decisions in 90% of cases. Plus Therapeutics plans to rebrand as Cerenome, Inc. in August 2026, continuing to develop integrated CNS cancer diagnostics and therapeutics.
Snail Games announced it will participate in Gamescom 2026 from August 26-30 in Cologne, Germany, showcasing an expanded portfolio including new IPs and a never-before-seen AAA game. Highlights include expansions of the flagship survival series "ARK:...
Snail Games announced its participation in Gamescom 2026, held in Cologne, Germany from August 26-30. The company will present an expanded portfolio including new content for its flagship survival series Ark: Survival Ascended, a new open universe MM...
Union Pacific and Canadian National Railway (CN) have signed a binding agreement to improve rail service across North America. The deal expands Union Pacific's operating rights on CN's Elgin, Joliet and Eastern corridor near Chicago and grants CN new...
Oak Valley Bancorp reported a Q2 2026 net income of $5.1 million, slightly down from previous periods due to higher expenses and lower non-interest income. Loan growth and improved loan yields increased net interest income, while non-performing asset...
BHP Group met its FY2026 production and cost targets, with iron ore and copper output as expected and copper prices significantly above consensus. The company reduced net debt from $14.7 billion to about $9 billion, helped by free cash flow, better w...
